Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Descriptor ID |
D002295
|
| MeSH Number(s) |
C04.557.470.200.430
|
| Concept/Terms |
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 5 | 0 | 5 |
| 2000 | 3 | 0 | 3 |
| 2001 | 5 | 1 | 6 |
| 2002 | 4 | 0 | 4 |
| 2003 | 8 | 2 | 10 |
| 2004 | 5 | 1 | 6 |
| 2005 | 3 | 0 | 3 |
| 2006 | 11 | 1 | 12 |
| 2007 | 7 | 0 | 7 |
| 2008 | 9 | 2 | 11 |
| 2009 | 5 | 0 | 5 |
| 2010 | 12 | 0 | 12 |
| 2011 | 4 | 0 | 4 |
| 2012 | 6 | 0 | 6 |
| 2013 | 4 | 0 | 4 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 5 | 0 | 5 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 8 | 0 | 8 |
| 2020 | 2 | 0 | 2 |
| 2021 | 4 | 0 | 4 |
| 2022 | 5 | 0 | 5 |
| 2023 | 5 | 0 | 5 |
| 2024 | 1 | 1 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions. Hum Pathol. 2025 Jun; 160:105823.
-
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes. Clin Genitourin Cancer. 2025 Aug; 23(4):102356.
-
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211. Urol Oncol. 2025 03; 43(3):188.e9-188.e17.
-
The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN). Urol Oncol. 2025 06; 43(6):390.e1-390.e11.
-
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol. 2025 Apr; 8(2):258-262.
-
The Upper TRACT Endometry Score: Development and Internal Validation of an Objective Measure of Variables That Affect Endoscopic Procedures for Upper Tract Urothelial Carcinoma. J Urol. 2025 Apr; 213(4):467-474.
-
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2025 Feb; 23(1):102284.
-
Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience. Am J Clin Pathol. 2024 Nov 04; 162(5):492-499.
-
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10). Urol Oncol. 2025 05; 43(5):330.e1-330.e9.
-
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011. Cancer. 2025 Jan 01; 131(1):e35601.